Minor histocompatibility antigens in allogeneic hematopoietic cell transplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 1, 2006, Pages 31-36

  Warren, Edus H ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Graft versus host; Graft versus leukemia; H Y; Minor histocompatibility

Indexed keywords

BLOOD GROUP H ANTIGEN; GENE PRODUCT; HY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION; GENETIC VARIABILITY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; LONG TERM CARE; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION; Y CHROMOSOME;

EID: 33644635038     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000209292.57041.1d     Document Type: Review

References (46)

1. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292:832-843.
2. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292:895-902.
3. Rotzschke O, Falk K, Wallny HJ, et al. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 1990; 249:283-287.
4. Wallny HJ, Rammensee HG. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343:275-278.
5. Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269:1588-1590.
6. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268:1476-1480.
7. Chao NJ. Minors come of age: minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10:215-223.
8. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91:2197-2207.
9. Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science 1997; 278:675-680.
10. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003; 423:825-837.
11. Dolstra H, de Rijke B, Fredrix H, et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J Immunol 2002; 32:2748-2758.
12. + T cell responses after allogeneic HCT.
13. + T-helper cells in H-Y-mismatched transplantation. Lancet 2003; 362:610-615.
14. Torikai H, Akatsuka Y, Miyazaki M, et al. A novel HLA-A*3303- restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol 2004; 173:7046-7054. This study shows that the TMSB4Y gene encodes a class I MHC-restricted H-Y antigen in what was heretofore considered its 5′-untranslated region, suggesting that the protein products of this gene are more extensive than was previously thought.
15. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6:273-281.
16. Pierce RA, Field ED, den Haan JM, et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999; 163:6360-6364.
17. Vogt MH, de Paus RA, Voogt PJ, et al. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 2000; 95:1100-1105.
18. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000; 164:2807-2814.
19. Vogt MH, Goulmy E, Kloosterboer FM, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000; 96:3126-3132.
20. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99:3027-3032.
21. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004; 199:1133-1142. This study demonstrates that the DBY gene stimulates both B and T cell responses after sex-mismatched (female → male) allogeneic HCT.
22. van Leeuwen A, Goulmy E, van Rood JJ. Major histocompatibility complexrestricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. J Exp Med 1979; 150:1075-1083.
23. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103:353-359. This study demonstrates that DBY stimulates antibody responses in a large fraction of sex-mismatched allogeneic HCT recipients, and suggests that the concept of a minor H antigen as the target of an allogeneic T cell response should be expanded to encompass the occurrence of humoral responses to alloantigens.
24. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105:2973-2978. This study demonstrates a high prevalence of antibody responses to Y chromosome gene products in sex-mismatched (female → male) allogeneic hematopoietic cell transplant recipients and a correlation with chronic GVHD as well as maintenance of disease remission, suggesting a role for humoral responses against H-Y antigens in both GVT activity and chronic GVHD.
25. Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103:347-352. This large, statistically compelling retrospective study showed that male recipients of female hematopoietic cell grafts benefit from a selective graft-versus-leukemia effect that is independent of GVHD.
26. Kircher B, Stevanovic S, Urbanek M, et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117:935-939.
27. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100:2742-2747.
28. Kircher B, Wolf M, Stevanovic S, et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J Immunother 2004; 27:156-160.
29. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18:798-808.
30. Takami A, Sugimori C, Feng X, et al. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response. Bone Marrow Transplant 2004; 34:703-709.
31. Tykodi SS, Warren EH, Thompson JA, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10:7799-7811.
32. Klein CA, Wilke M, Pool J, et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 2002; 196:359-368.
33. Fujii N, Hiraki A, Ikeda K, et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 2002; 73:1137-1141.
34. Miyazaki M, Akatsuka Y, Nishida T, et al. Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clin Immunol 2003; 107:198-201.
35. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810-11813.
36. + donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002; 8:2052-2060.
37. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005; 19:83-90. This study demonstrates that GVT responses occurring after DLI given for treatment of post-transplant relapse are associated with diverse T cell responses directed at multiple distinct minor H antigens.
38. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106:705-714.
39. Yang XF, Wu CJ, McLaughlin S, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001; 98:7492-7497.
40. Yang XF, Wu CJ, Chen L, et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002; 62:5517-5522.
41. Bellucci R, Wu CJ, Chiaretti S, et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103:656-663. This study demonstrates that GVT reactions after DLI for multiple myeloma are associated with antibody responses against nonpolymorphic but highly expressed antigens.
42. Bellucci R, Alyea EP, Chiaretti S, et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005; 105:3945-3950. This study provocatively suggests that antibody responses to BCMA, a nonpolymorphic cell surface receptor expressed by myeloma cells, may contribute to GVT reactions after DLI for multiple myeloma.
43. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB*40101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191:625-630.
44. Jager E, Nagata Y, Gnjatio S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97:4760-4765.
45. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27:234-236.
46. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307:1072-1079. This is a comprehensive analysis of common DNA variation in the human genome, which suggests that the total number of potential minor H antigens is likely to be quite large.